ResearchSafe

Fractyl's oral GLP-1 gene therapy just got EMA green light, thoughts?

Posted by tiredmira in Research & News - 9 points, 4 comments.

So this actually showed up on my radar this week and I can't stop thinking about it. Fractyl's oral GLP-1 gene therapy got the EMA green light, which feels like a pretty big deal for anyone tracking the peptide space.

My honest take? It's promising but I'm not ready to call it a win yet. The idea of replacing daily injections with a one-time oral dose sounds almost too clean. For me the appeal is obvious, I hate pinning and the adherence fatigue on weekly shots is real, I already see it in friends who started strong and now skip weeks.

But gene therapy is not a peptide. It's a whole different risk profile and the long term data just isn't there. Curious how others are framing it. Is this the thing that finally pushes GLP-1 access mainstream, or are we getting excited over Phase 2 vibes dressed up as a regulatory milestone?

Would love to hear from anyone actually following Fractyl's trial design more closely than me. What am I missing?

Comments

  • grinder265: Ngl I've been tracking this since the Revita data dropped a while back. The EMA move feels more like "this technology platform is sound" than "GLP-1 in a pill is here tomorrow". That's a real distinction people are kinda glossing over. The adherence argument hits hard for me, I hear the same thing from friends on tirz. But swapping a weekly pin for a one time gene therapy is wild if you think about what you're actually signing up for. No off switch, no dose adjustment, if your receptors downreg
  • dad_humble: Yeah the no off switch part is what gets me too... Once it's in there it's in there. For me the scary thought is not even the side effects, it's the unknown 10+ years out. Nobody knows what long term GLP-1 overexpression does to the gut-brain axis or pancreatic tissue.
  • tiredmira: Honestly the gut-brain axis piece is what I come back to too. Like we already know GLP-1s mess with hunger signaling in ways we're still figuring out, and that's with a drug you can stop. With this, if something weird shows up at year 5 or 10, you're stuck with it. For me the comparison that sticks is older gene therapies that looked fine at 2 years and then had issues pop up later. That lag is what worries me more than the acute stuff honestly. Did you see any actual durability data from thei
  • tiredmira: Yeah the "no off switch" thing is exactly what kept me up. With a peptide you can just stop, with this you're basically married to the outcome. And the Revita data was duodenal mucosal ablation right? Not the same mechanism as the oral gene therapy payload, so I'm not sure how much it actually predicts efficacy here either. You seeing any chatter on which vector they're using for the gut expression, AAV or LNP?

Community discussion - research and educational context only. Not medical advice.